Search Results - "CONSTENLA, Manuel"

Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group by VAN CUTSEM, Eric, MOISEYENKO, Vladimir M, RISSE, Marie-Laure, AJANI, Jaffer A, TJULANDIN, Sergei, MAJLIS, Alejandro, CONSTENLA, Manuel, BONI, Corrado, RODRIGUES, Adriano, FODOR, Miguel, CHAO, Yee, VOZNYI, Edouard

“…In the randomized, multinational phase II/III trial (V325) of untreated advanced gastric cancer patients, the phase II part selected docetaxel, cisplatin, and…”
Get full text

Evaluating health related quality of life in outpatients receiving anti-cancer treatment: results from an observational, cross-sectional study by Oh, Hae-Jin Suh, Menéndez, Ãngeles Flórez, Santos, Víctor Sacristán, Martínez, Ãngeles Rodríguez, Ribeiro, Francisca Fernández, Vilanova-Trillo, Lucía, Figueiras, Manuel Constenla, Ferreiros, Manuel Pereiro

“…Abstract Background The aim of the study was to assess health-related quality of life (HRQOL) in outpatients receiving anti-cancer treatment. Methods…”
Get full text

Quality of Life With Docetaxel Plus Cisplatin and Fluorouracil Compared With Cisplatin and Fluorouracil From a Phase III Trial for Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group by AJANI, Jaffer A, MOISEYENKO, Vladimir M, AWAD, Lucile, VAN CUTSEM, Eric, TJULANDIN, Sergei, MAJLIS, Alejandro, CONSTENLA, Manuel, BONI, Corrado, RODRIGUES, Adriano, FODOR, Miguel, CHAO, Yee, VOZNYI, Edouard

“…Therapy of patients with advanced gastric or gastroesophageal junction cancer should provide symptom relief and improve quality of life (QOL) because most…”
Get full text

Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study by Yubero, Alfonso, Barquín, Aranzazu, Estévez, Purificación, Pajares, Bella, Sánchez, Luisa, Reche, Piedad, Alarcón, Jesús, Calzas, Julia, Gaba, Lydia, Fuentes, José, Santaballa, Ana, Salvador, Carmen, Manso, Luis, Herrero, Ana, Taus, Ãlvaro, Márquez, Raúl, Madani, Julia, Merino, María, Marquina, Gloria, Casado, Victoria, Constenla, Manuel, Gutiérrez, María, Dosil, Alba, González-Martín, Antonio

“…Abstract Background: Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive (Pt-S)…”
Get full text

Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study by Schwenkglenks, Matthias, Pettengell, Ruth, Jackisch, Christian, Paridaens, Robert, Constenla, Manuel, Bosly, André, Szucs, Thomas D., Leonard, Robert

“…Background Chemotherapy-induced neutropenia (CIN) places patients at risk of life-threatening infections. While reduction of chemotherapy dose or delay of the…”
Get full text

Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study by Suh Oh, Hae-Jin, Flórez Menéndez, Ángeles, Sacristán Santos, Víctor, Fernández Ribeiro, Francisca, Vilanova-Trillo, Lucía, Constenla Figueiras, Manuel, Pereiro Ferreiros, Manuel

“…Despite growing interest in cutaneous adverse events (CAEs) and their management in patients with cancer, they are often underreported and there are no…”
Get full text

5-HT3 Receptor Antagonists for Prevention of Late Acute-Onset Emesis by Constenla, Manuel

“…OBJECTIVE To review the currently available literature on the efficacy of the 5–HT3 receptor antagonists in the prevention of late acute-onset…”
Get full text

Clinical Benefit With Docetaxel Plus Fluorouracil and Cisplatin Compared With Cisplatin and Fluorouracil in a Phase III Trial of Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group by Ajani, Jaffer A., Moiseyenko, Vladimir M., Tjulandin, Sergei, Majlis, Alejandro, Constenla, Manuel, Boni, Corrado, Rodrigues, Adriano, Fodor, Miguel, Chao, Yee, Voznyi, Edouard, Marabotti, Cindy, Van Cutsem, Eric

“…Purpose For patients with advanced gastric or gastroesophageal cancer (AGGEC) providing clinical benefit with improved palliation is highly desirable. However,…”
Get full text

Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study by Constenla, Manuel, Garcia-Arroyo, Ramon, Lorenzo, Isabel, Carrete, Nancy, Campos, Begoña, Palacios, Patricia

“…Previous studies have shown that the taxane, docetaxel, is effective in treating gastric cancer. The aim of this study was to assess the efficacy and safety of…”
Get full text

Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma : The V-325 study group by AJANI, Jaffer A, MOISEYENKO, Vladimir M, MARABOTTI, Cindy, VAN CUTSEM, Eric, TJULANDIN, Sergei, MAJLIS, Alejandro, CONSTENLA, Manuel, BONI, Corrado, RODRIGUES, Adriano, FODOR, Miguel, CHAO, Yee, VOZNYI, Edouard

“…For patients with advanced gastric or gastroesophageal cancer (AGGEC) providing clinical benefit with improved palliation is highly desirable. However, a…”
Get full text

Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme by Cueva, Juan F., Palacio, Isabel, Churruca, Cristina, Herrero, Ana, Pardo, Beatriz, Constenla, Manuel, Santaballa, Ana, Manso, Luis, Estévez, Purificación, Maximiano, Constanza, Legerén, Marta, Marquina, Gloria, de Juan, Ana, Quindós, María, Sánchez, Luisa, Barquin, Arantzazu, Fernández, Isaura, Martín, Cristina, Juárez, Asunción, Martín, Teresa, García, Yolanda, Yubero, Alfonso, Gallego, Alejandro, Martínez Bueno, Alejandro, Guerra, Eva, González-Martín, Antonio

“…To describe patient characteristics, effectiveness and safety in a real-world population treated with niraparib in the Spanish expanded-access programme. This…”
Get full text

Evaluation of Spanish hospitals participating in the Quality Oncology Practice Initiative program by Lopez, Rafael, Antón, Antonio, Aranda, Enrique, Carrato, Alfredo, Constenla, Manuel, Cruz-Hernández, Juan J., Díaz-Rubio, Eduardo, Feyjóo, Margarita, García-Foncillas, Jesús, Gascón, Pere, Guillem, Vicente, Lugo, Ilse, Camps, Carlos

“…Abstract only 222 Background: Measuring and tracking quality of care is highly relevant in today’s healthcare. The Quality Oncology Practice Initiative (QOPI)…”
Get full text

Implementation of the quality training program in Spain by Lopez, Rafael, Anton, Antonio, Aranda, Enrique, Carrato, Alfredo, Constenla, Manuel, Cruz, Juan Jesús, Diaz-Rubio, Eduardo, Feyjoo, Margarita, Garcia-Foncillas, Jesus, Gascon, Pedro, Guillem, Vicente, Lugo, Ilse, Camps, Carlos

“…Abstract only 11 Background: The ECO Foundation is a collaboration of experts representing the major Spanish hospitals in the pursuit of excellence in cancer…”
Get full text

Dynamic perspective of neutrophil-lymphocyte ratio in metastatic gastric cancer by Cousillas, Antia, Gallardo Martin, Elena, Vazquez Tunas, Lidia Maria, Carou, Iria, Quiroga, Nazaret, Azpitarte, Cristina, Jato, Cristina Lopez, Garcia Arroyo, Francisco Ramon, Constenla, Manuel

“…Abstract only…”
Get full text

Multivariate analysis of febrile neutropenia occurrence in patients with non‐Hodgkin lymphoma: data from the INC‐EU Prospective Observational European Neutropenia Study by Pettengell, Ruth, Bosly, André, Szucs, Thomas D., Jackisch, Christian, Leonard, Robert, Paridaens, Robert, Constenla, Manuel, Schwenkglenks, Matthias

“…Summary Myelosuppression, particularly febrile neutropenia (FN), are serious dose‐limiting toxicities that occur frequently during the first cycle of…”
Get full text

Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study by Pettengell, Ruth, Schwenkglenks, Matthias, Leonard, Robert, Bosly, André, Paridaens, Robert, Constenla, Manuel, Szucs, Thomas D., Jackisch, Christian

“…Goals of work Neutropenia is a life-threatening, dose-limiting toxicity of many chemotherapy regimens. The goals of this study were to assess the incidence and…”
Get full text

The Quality Oncology Practice Initiative Program: Experience in Spain by Lopez, Rafael, Anton, Antonio, Aranda, Enrique, Carrato, Alfredo, Constenla, Manuel, Cruz, Juan Jesús, Díaz-Rubio, Eduardo, Feyjoo, Margarita, García Foncillas, Jesús, Gascon, Pedro, Guillem, Vicente, Lugo, Ilse, Camps, Carlos

“…Abstract only e18267 Background: Patient care quality is a discipline with enormous relevance in today’s healthcare. Quality Oncology Practice Initiative…”
Get full text

Implementation of the Quality Training Program in Spain by Lopez, Rafael, Anton, Antonio, Aranda, Enrique, Carrato, Alfredo, Constenla, Manuel, Cruz, Juan Jesús, Díaz-Rubio, Eduardo, Feyjoo, Margarita, García Foncillas, Jesús, Gascon, Pedro, Guillem, Vicente, Lugo, Ilse, Camps, Carlos

“…Abstract only e18296 Background: The ECO Foundation is a collaboration of experts representing the major Spanish hospitals in the pursuit of excellence in…”
Get full text

Strategies for reducing grade 2 and 3 adverse events due to immunotherapy in a Spanish university hospital by Gomez, Ana, Gómez Solana, Paloma, Ruiz, Elena, Anton, Antonio, Aranda, Enrique, Camps, Carlos, Constenla, Manuel, Cruz, Juan Jesús, Díaz-Rubio, Eduardo, Feyjoo, Margarita, García Foncillas, Jesús, Gascon, Pedro, Guillem, Vicente, Lopez, Rafael, Lugo, Ilse, Carrato, Alfredo

“…Abstract only e18295 Background: To develop an improvement project, the Lung Cancer Unit of Ramón y Cajal Hospital (Madrid) analyzed 45 patients treated with…”
Get full text

Comparative Study of Survival following Videothoracoscopic Lobectomy Procedures for Lung Cancer: Single- versus Multiple-port Approaches by Borro, José M, Regueiro, Francisco, Pertega, Sonia, Constenla, Manuel, Pita, Salvador

“…Abstract Introduction Video-assisted thoracoscopic surgery has become the technique of choice in the early stages of lung cancer in many centers although there…”
Get full text